{"name":"XIANG YANQUN","slug":"xiang-yanqun","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Capecitabine/Placebo combined with toripalimab","genericName":"Capecitabine/Placebo combined with toripalimab","slug":"capecitabine-placebo-combined-with-toripalimab","indication":"Gastric or gastroesophageal junction cancer (Phase 3 trial indication)","status":"phase_3"},{"name":"GP Combined With Camrelizumab","genericName":"GP Combined With Camrelizumab","slug":"gp-combined-with-camrelizumab","indication":"Likely advanced or metastatic solid tumors (specific indication under phase 3 evaluation not definitively confirmed in public sources)","status":"phase_3"},{"name":"GP combined with Tislelizumab","genericName":"GP combined with Tislelizumab","slug":"gp-combined-with-tislelizumab","indication":"Advanced or metastatic solid tumors (specific indication under investigation in Phase 3 trial)","status":"phase_3"},{"name":"TPC combined with Tislelizumab","genericName":"TPC combined with Tislelizumab","slug":"tpc-combined-with-tislelizumab","indication":"Advanced or metastatic solid tumors (specific indication under investigation in Phase 3)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Irinotecan Liposomal combined With Nituzumab","genericName":"Irinotecan Liposomal combined With Nituzumab","slug":"irinotecan-liposomal-combined-with-nituzumab","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Capecitabine/Placebo combined with toripalimab","genericName":"Capecitabine/Placebo combined with toripalimab","slug":"capecitabine-placebo-combined-with-toripalimab","phase":"phase_3","mechanism":"Capecitabine is a prodrug chemotherapy that converts to fluorouracil to inhibit thymidylate synthase, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.","indications":["Gastric or gastroesophageal junction cancer (Phase 3 trial indication)"],"catalyst":""},{"name":"Irinotecan Liposomal combined With Nituzumab","genericName":"Irinotecan Liposomal combined With Nituzumab","slug":"irinotecan-liposomal-combined-with-nituzumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GP Combined With Camrelizumab","genericName":"GP Combined With Camrelizumab","slug":"gp-combined-with-camrelizumab","phase":"phase_3","mechanism":"GP (gemcitabine/cisplatin chemotherapy) combined with camrelizumab (a PD-L1 inhibitor) works by killing cancer cells directly while simultaneously unleashing immune responses against tumors.","indications":["Likely advanced or metastatic solid tumors (specific indication under phase 3 evaluation not definitively confirmed in public sources)"],"catalyst":""},{"name":"GP combined with Tislelizumab","genericName":"GP combined with Tislelizumab","slug":"gp-combined-with-tislelizumab","phase":"phase_3","mechanism":"GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction.","indications":["Advanced or metastatic solid tumors (specific indication under investigation in Phase 3 trial)"],"catalyst":""},{"name":"TPC combined with Tislelizumab","genericName":"TPC combined with Tislelizumab","slug":"tpc-combined-with-tislelizumab","phase":"phase_3","mechanism":"TPC combined with Tislelizumab uses chemotherapy to damage cancer cells while Tislelizumab blocks PD-1 to enhance immune recognition and attack of tumors.","indications":["Advanced or metastatic solid tumors (specific indication under investigation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":4,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}